A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer (Q46495105)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2005

edit

Language	Label	Description	Also known as
English	A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer	scientific article published in March 2005

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

title

A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

author name string

Joan Carles Galcerán

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Romà Bastus Piulats

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Javier Martín-Broto

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Pablo Maroto Rey

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Miquel Nogué Aligué

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Montserrat Domenech Santasusana

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Angels Arcusa Lanza

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Joaquim Bellmunt Molins

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Catherine Colin

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

Atika Girard

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

publication date

1 March 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

published in

Clinical and Translational Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

volume

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

page(s)

66-73

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

cites work

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FBF02710012

retrieved

21 January 2018

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FBF02710012

retrieved

21 January 2018

Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 1998

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy in advanced prostate cancer: a silk purse?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early detection of prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flutamide in Hormone-Resistant Prostatic Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine depolymerizes microtubules by binding to tubulin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine Phosphate Sodium

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15899211

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/BF02710012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

PubMed publication ID

15899211

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15899211

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/15899211

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46495105&oldid=2207908256"